Efficacy and safety of long-term treatment with dupilumab for moderate to severe atopic dermatitis

被引：0
|
作者：
Ikeda, M. [1 ,2 ]
Uehara, H. [1 ,2 ]
Tsuge, M. [1 ,2 ]
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat Acute Med, Okayama, Japan
[2] Fukuyama City Hosp, Dept Pediat, Fukuyama, Hiroshima, Japan
来源：
ALLERGY | 2019年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
PD0311
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [21] Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
    Mareschal, Adrien
    Puzenat, Eve
    Aubin, Francois
    [J]. ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)
  • [22] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [23] Treatment satisfaction with long-term dupilumab treatment in adult patients with moderate-to-severe atopic dermatitis (LIBERTY AD OLE)
    Thaci, D.
    Blauvelt, A.
    Hussain, I
    Bastian, M.
    Sun, X.
    Chao, J.
    Levit, N. A.
    Rossi, A. B.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 65
  • [24] Patient wellbeing and perception of treatment effect with long-term dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis
    Simpson, E. L.
    Beissert, S.
    Beck, L. A.
    Zhang, H.
    Aamodt, K.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E139
  • [25] Long-term results of dupilumab in the treatment of moderate to severe atopic dermatitis: The experience of five reference dermatology units in Spain
    Juan Pereyra-Rodriguez, Jose
    Ruiz Villaverde, Ricardo
    Dominguez-Cruz, J. J.
    Alcantara Luna, Sara
    Martinez Pilar, Leandro
    Ramon Jimenez, Juan
    Armario-Hita, Jose C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB135 - AB135
  • [26] Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Thaci, Diamant
    de Bruin-Weller, Marjolein
    Deleuran, Mette
    Kataoka, Yoko
    Friedman, Adam J.
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Chen, Zhen
    Avetisova, Elena
    Zhang, Annie
    Nguyen, Tien, V
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 71 - 72
  • [27] Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
    Jang, Dong Hyek
    Heo, Seok Jae
    Jung, Hye Jung
    Park, Mi Yeon
    Seo, Seong Jun
    Ahn, Jiyoung
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 12
  • [28] Assessment of long-term safety and efficacy of Dupilumab therapy in patients with moderate-to-severe atopic dermatitis in the UAE: A real-life observational study
    Abdulwahhab, Waqas S.
    Zainalabdin, Sham
    Al-Areqi, Noor
    Amrane, Imene
    Alhashmi, Ahmed
    Aburuz, Omar
    Akour, Amal
    Beiram, Rami
    Aburuz, Salahdein
    [J]. PHARMACY PRACTICE-GRANADA, 2024, 22 (02):
  • [29] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [30] Dupilumab provides long-term efficacy over 2-5 years in adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Bissonnette, R.
    Wollenberg, A.
    Simpson, E. L.
    Thaci, D.
    Praestgaard, A.
    Aamodt, K.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E140
12345